The t(8;21)(q22;q22) translocation, present in B5% of adult acute myeloid leukemia (AML) cases, produces the AML1/ETO (AE) fusion protein. Dysregulation of the Pit/Oct/Unc (POU) domain-containing transcription factor POU4F1 is a recurring abnormality in t(8;21) AML. In this study, we showed that POU4F1 overexpression is highly correlated with, but not caused by, AE. We observed that AE markedly increases the self-renewal capacity of myeloid progenitors from murine bone marrow or fetal liver and drives the expansion of these cells in liquid culture. POU4F1 is neither necessary nor sufficient for these AE-dependent properties, suggesting that it contributes to leukemia through novel mechanisms. To identify targets of POU4F1, we performed gene expression profiling in primary mouse cells with genetically defined levels of POU4F1 and identified 140 differentially expressed genes. This expression signature was significantly enriched in human t(8;21) AML samples and was sufficient to cluster t(8;21) AML samples in an unsupervised hierarchical analysis. Among the most highly differentially expressed genes, half are known AML1/ETO targets, implying that the unique transcriptional signature of t(8;21) AML is, in part, attributable to POU4F1 and not AML1/ETO itself. These genes provide novel candidates for understanding the biology and developing therapeutic approaches for t(8;21) AML. Leukemia (2010) 24, 950-957;
Introduction
The t(8;21)(q22;q22) translocation produces an in-frame fusion of the first five exons of AML1 (RUNX1) to all but the first exon of ETO (MTG8). 1 This translocation is detectable in B10% of de novo acute myeloid leukemia (AML) cases of the French-American-British M2 subtype and in B5% of all AML cases. 2 AML1 is the DNA-binding subunit of CBF (core-binding factor), a multimeric transcription factor complex that includes CBFb and additional transcriptional cofactors. The chimeric AML1/ ETO (AE) protein exerts dominant negative effects on genes typically regulated by CBF. 3 ETO, also a transcription factor, contains four nervy homology regions that contribute directly to the negative regulation of CBF-responsive genes. 4 Despite these effects on gene regulation, AE is not sufficient to cause AML, [5] [6] [7] [8] implying that additional genetic events are required.
Genome-wide expression profiling of primary human AML samples, performed by several groups, has identified a robust gene expression profile that distinguishes t(8;21) from other AML subtypes. 9, 10 ETO is part of the t(8;21) expression signature. This is not unexpected, as most of the ETO coding sequence is contained within the AML1/ETO fusion transcript. These studies have also shown that the POU4F1 gene is consistently dysregulated in t(8;21) human patient samples. 9, 10 POU4F1 is a transcription factor, originally identified in the rat brain. 11 The mouse and human orthologs are highly homologous (95% nucleic acid identity, 99% amino acid identity). POU4F1 contains a homeodomain and a Pit/Oct/Unc (POU)-specific domain, both of which are required for DNA binding. 11 Pou4f1 is important for embryonic brain development and is expressed beginning at E11.0 in mice, 12 but has no reported role in normal or leukemic hematopoiesis. Pou4f1 null mice die postnatally with developmental anomalies in both the central and peripheral nervous system. 13, 14 The striking correlation between AML1/ETO and POU4F1 expression in human AML led us to hypothesize that POU4F1 might be a transcriptional target of AML1/ETO. Surprisingly, we found that POU4F1 dysregulation is not caused by AML1/ETO and that POU4F1 is dispensable for AE function in vitro, but it is an important driver of the unique transcriptional profile associated with t(8;21) AML.
Materials and methods

Plasmids
Recombinant murine stem cell proviral plasmids Murine Stem Cell Virus (MSCV) 2.2-ires-GFP (MIG) and MAIG (MSCV2.2-AML1/ETO-ires-GFP) were provided by Michael Tomasson (Washington University, St Louis, MO, USA). MSCV2.2-ires-YFP (MIY) was created by removing the GFP cDNA from MIG and replacing it with YFP from pEYFP-N1 (Clontech, Mountain View, CA, USA). MPIY (MSCV 2.2-Pou4f1-ires-YFP) and MPIG (MSCV2.2-Pou4f1-ires-GFP) were generated by subcloning the mouse Pou4f1 cDNA (provided by Eric Turner, University of CA, San Diego, CA, USA) into MIY or MIG, respectively.
Mice
Pou4f1 (Brn3a) mutant mice were provided by Eric Turner (University of CA). 15 Embryos from timed mating were genotyped by PCR (primer sequences are provided in Supplementary Table 1 ). Sca þ /GFP and Sca þ /AE mice were generated as described previously. 8, 16 All mice were backcrossed at least 10 generations to a C57BL/6J background.
Real-time PCR analysis
RNA was made in Trizol LS (Invitrogen, Carlsbad, CA, USA). All samples, excluding RNA from human AML samples, were treated with DNAse (Roche, Palo Alto, CA, USA). cDNA was made from RNA using Moloney Murine Leukemia Virus (M-MLV) reverse transcriptase (Promega, Madison, WI, USA). Quantitative real-time PCR was performed using TaqMan Universal PCR Master Mix (Roche) (primer and probe sequences are provided in Supplementary Table 1 ). All samples were run in triplicate on a 7300 Real-Time PCR system (Applied Biosystems, Foster City, CA, USA) and analyzed using the relative standard curve method.
Retroviral transduction
Retroviral supernatants were generated by transient transfection of 293T cells with Ecopac (Cell Genesys, Foster City, CA, USA) and MSCV-based retroviral constructs. Forty-eight hours after transfection, retroviral supernatants were harvested and titered on 3T3 cells using flow cytometry.
Bone marrow cells were cultured in complete media (RPMI containing 1% L-glutamine, 20% fetal bovine serum) supplemented with recombinant hematopoietic cytokines (100 ng/ml stem cell factor, 6 ng/ml interleukin-3, 50 ng/ml Fms-related tyrosine kinase 3 ligand and 10 ng/ml thrombopoietin; all from Peprotech, Rocky Hill, NJ, USA) for 48 h. A total of 3.0-4.5 Â 10 6 cells were infected on two consecutive days by centrifugation at 2500 g for 90 min in the presence of 10 mcg/ml polybrene (Sigma, St Louis, MO, USA) and 33 uM HEPES with retroviral supernatants using multiplicities of infection ranging from 1.5 to 3. Two days after infection, the cells were seeded in cytokine-supplemented media at 10 5 cells/ml in triplicate. In some experiments, transduced cells were selected by sorting on green fluorescent protein (GFP) or yellow fluorescent protein (YFP) (MoFlo, Beckman Coulter, Fullerton, CA, USA) before initiating the cultures. Cells were counted twice weekly and replated in fresh media, maintaining a concentration of 10 5 cells/ml. The proportion of transduced cells was monitored weekly by flow cytometry (FACScan, Becton Dickinson, Franklin Lakes, NJ, USA).
Hematopoietic progenitor analysis
Bone marrow cells from adult mice or 14.5-16.5 dpc fetal liver cells were transduced, as described above. Forty-eight hours after the first round of infection, the cells were washed three times with RPMI, plated (6.7 Â 10 3 cells/ml for bone marrow or 3.3 Â 10 4 cells/ml for fetal liver) in cytokine-supplemented methylcellulose media (MethoCult M3434, Stem Cell Technologies, Vancouver, BC, Canada) and incubated at 37 1C in 5% CO 2 . Seven days after plating, the colonies were examined under a fluorescence microscope. GFP þ or YFP þ colonies were individually selected, disrupted and replated at one colony-equivalent per well in 24-well plates containing fresh methylcellulose media. Colonies were scored for survival and serially replated weekly.
Gene expression profiling
Murine 14.5-16.5 dpc fetal liver cells were sorted for GFP or YFP expression 48 h after retroviral transduction. Three experimental groups were generated: 'Pou4f1 null' (Pou4f1 À/À cells transduced with MIY), 'Pou4f1 wild type' (Pou4f1 þ / þ cells transduced with MIY) and 'Pou4f1 high' (Pou4f1 þ / þ cells transduced with MPIY). Three independent samples were generated for each group (n ¼ 9 total samples). RNA was purified using Trizol LS, quantified by ultraviolet spectroscopy (Nanodrop Technologies, Wilmington, DE, USA), and qualitatively assessed using a BioAnalyzer 2100 and the RNA NanoChip assay (Agilent Technologies, Palo Alto, CA, USA). All samples were linear amplified, labeled and hybridized to Affymetrix MOE430v2.0 GeneChip microarrays (Affymetrix, Santa Clara, CA, USA) using standard protocols from the Siteman Cancer Center Multiplexed Gene Analysis Core Facility (for protocols, see http://pathimm.wustl.edu/research/lcglab/ lcgexp.php). Data are available from the Gene Expression Omnibus (GSE19997).
Probe raw signal intensities were summarized into probeset values using robust multiarray average, 17 and samples were quantile normalized. Only probesets called 'Present' by the MAS5 algorithm using Affymetrix GCOS (Santa Clara, CA, USA) software in all triplicates of at least one experimental group were retained for cluster and differential gene expression analysis (n ¼ 17 568 probesets). The overall expression profiles were highly similar for all samples (average Pearson correlation r ¼ 0.959), except for one from the wild-type group (average Pearson coefficient ¼ 0.923 compared with the remaining 8 samples). This sample was retained, as the results of downstream analysis were not affected. We performed ANOVA (one-way analysis of variance) to identify probesets exhibiting differential expression between experimental groups. We performed 17 568 statistical tests, and applied q-value to the resulting P-values to estimate the genome-wide false discovery rate. Gene ontology enrichment analysis was performed using DAVID. 18 Total RNA from 111 de novo M0-M7 human AML samples was profiled on Affymetrix U133 þ 2 arrays as described previously. 19 Data are available from the Gene Expression Omnibus (GSE10358). Human orthologs of the dysregulated murine genes were identified (n ¼ 285 probesets) using Bio-Mart. 20 Testing for the enrichment of the Pou4f1 gene set in human AML samples was performed using Gene Set Enrichment Analysis. 21 Samples with or without t(8;21) were compared, and genes were ranked based on the correlation between their expression and the class distinction using both signal2noise and ratio-of-classes gene-ranking metrics. 21 Ward's hierarchical clustering was performed using Spotfire DecisionSite 8.2 (TIBCO Software Inc., Somerville, MA, USA). The P-value of the t(8;21) clustering was assessed by determining the number of times that a random selection of 285 probesets would result in the t(8;21) samples being nearest neighbors (distance metric ¼ 1ÀPearson correlation), divided by the number of random samplings (n ¼ 10 000). The POU4F1-independent gene expression profile was identified by removing the probesets for POU4F1 and its targets from the human AML data. Probesets with fewer than 25% present calls or a coefficient of variation (CV) o0.5 were also removed. The remaining 13 700 probesets were used to cluster the AML samples with or without t(8;21). Significant differences in expression were identified by significance analysis of microarrays (SAM) using a false discovery rate threshold o0.05. 22
Results
POU4F1 is associated with t(8;21) AML
We along with others have noted that POU4F1 expression is dysregulated in t(8;21) AML. 9, [23] [24] [25] [26] [27] We performed gene expression profiling using primary human samples and found that POU4F1 is not expressed in normal human CD34 þ bone marrow cells or in AML samples from most French, American, British (FAB) subtypes ( Figure 1 ). High POU4F1 expression is restricted to M2 samples, with the highest levels noted in t(8;21)positive AML. To confirm these results, we performed quantitative real-time PCR using three samples with t(8;21) and nine randomly selected M2 samples without t (8;21) . The t(8;21) samples tested had significantly higher levels of POU4F1 expression compared with M2 samples lacking t(8;21) (Po0.001) ( Figure 1 ).
POU4F1 overexpression is AE independent
We hypothesized that the high POU4F1 expression in t(8;21) AML is caused by altered transcriptional activity mediated by AE.
Transient transfection of K562 cells with a construct containing AE (MAIG) or a control (MIG) plasmid did not increase POU4F1 mRNA above baseline levels ( Figure 2 ). Next, we infected primary mouse bone marrow cells with MAIG or MIG retroviruses. The cells were placed in culture and serial samples were collected for quantitative real-time PCR analysis to measure AE and Pou4f1 expression. AE mRNA was readily detectable in cells infected with MAIG, but Pou4f1 levels were not increased in cells expressing AE ( Figure 2 ). Similar results were obtained when bone marrow cells were first enriched for stem/progenitors by cell sorting (lineage-Kit þ Sca þ) before retroviral transduction (not shown). Finally, Pou4f1 levels were similar in bone marrow cells from mice heterozygous for an AE allele targeted to the Sca1 locus, compared with control Sca þ /GFP mice (Figure 2 ). Taken together, these data suggest that high POU4F1 expression, although correlated with t(8;21), is not caused by AE.
Role of POU4F1 in AE-dependent hematopoietic cell growth
To test the impact of AE and Pou4f1 on the survival and proliferation of hematopoietic cells in vitro, we performed retroviral transduction of primary murine bone marrow cells. Transduced cells were enriched by flow sorting for GFP and/or YFP expression, and cultured in cytokine-supplemented media. Cells transduced with Pou4f1 (MPIY) or empty vector (MIY) died within 2 weeks, whereas cells transduced with AE (with or without Pou4f1) expanded rapidly beyond 3 weeks ( Figure 3 ). Coexpression of Pou4f1 with AE provided no consistent growth advantage compared with AE alone.
Next, we performed long-term liquid culture of unsorted, retrovirally transduced cells and monitored the proportion of cells expressing GFP (AE reporter) and/or YFP (Pou4f1 reporter). Once again, cells infected with Pou4f1 alone were rapidly lost, whereas cells transduced with AE (with or without Pou4f1) had rapid and indistinguishable growth kinetics (Figure 3 ). In three independent experiments, the percentage of cells expressing AE only (GFP þ YFPÀ) expanded 8.1-fold (range ¼ 5.4-9.6) over 6 weeks, compared with a 0.6-fold increase (range ¼ 0.14-6) for AE/Pou4f1 double-positive cells. Although the growth of AE and AE/Pou4f1positive cells is similar, the growth is attributable to an increasing population of AE single-positive cells. Therefore, the slight decrease in growth seen in the AE/Pou4f1 population suggests that Pou4f1 may have a modest inhibitory effect on cell growth stimulated by the presence of AE, although this difference was not statistically significant (P ¼ 0.22, two-tailed paired t-test).
Pou4f1 is not required for AE-induced myeloid progenitor self-renewal
To test the importance of these genes for self-renewal of bone marrow myeloid progenitors, we performed serial replating of colonies retrovirally transduced with AE or Pou4f1 into cytokine-supplemented methocellulose media. In three independent experiments, colonies infected with the AE virus could be replated for at least 5 weeks (mean ¼ 17; range ¼ 15-20 per 24 colonies plated), which was significantly longer compared with colonies infected with the Pou4f1 virus (mean ¼ 2; range ¼ 1-4 per 24 colonies plated; Po0.001) or the control virus (mean ¼ 3; range ¼ 0-5; Po0.001), indicating that AE, but not Pou4f1, is sufficient to enhance progenitor self-renewal ( Figure 4 ). To determine whether cells required Pou4f1 to selfrenew, we serially replated colonies from Pou4f1 À/À , Pou4f1 þ /À or Pou4f1 þ / þ fetal liver cells infected with AE or the control (Figure 4 ). Therefore, AE promotes self-renewal of myeloid progenitors independent of Pou4f1.
Pou4f1-dependent transcriptional profile
As POU4F1 dysregulation is not caused by AE, we reasoned that POU4F1 might regulate factors that can cooperate with AE in leukemogenesis. Therefore, we used microarray analysis to determine the gene expression profile induced by POU4F1. RNA was obtained from flow-sorted murine fetal liver cells expressing high, wild-type or null levels of Pou4f1. The global gene expression profiles of all samples were highly similar (495% correlated); suggesting that overexpression of Pou4f1 did not dramatically alter the global transcriptional state of murine fetal liver cells, compared with wild-type or Pou4f1 À/À cells. We identified 167 probesets (140 unique genes) that were differentially expressed between at least two experimental groups (Supplementary Table 2 ). Probeset comparisons were significant between cells expressing high levels of Pou4f1 compared with cells expressing endogenous levels or no Pou4f1. The genes are enriched in several biological pathways relevant for cancer ( Supplementary Table 3 ). Pou4f1 itself is not part of the gene set, as the Pou4f1 probesets on the microarray are all 3 0 of sequences contained within the transduced Pou4f1 cDNA. We next sought to determine whether the set of 140 Pou4f1regulated genes discovered in mouse cells was relevant for human AML. As POU4F1 is highly expressed in t(8;21) human AML samples, we hypothesized that the human orthologs of the mouse Pou4f1 gene set would be enriched in a comparison of AML samples with or without t (8;21) . To test this hypothesis, we applied Gene Set Enrichment Analysis to the expression profiles of 111 human AML samples using ratio-of-classes and signal2noise (similar results obtained with both metrics). Significant enrichment of the Pou4f1 gene set was shown in t(8;21)-positive samples (false discovery rate q-value o0.001), suggesting that the Pou4f1 expression signature is robust across species ( Figure 5 ).
Next, we performed unsupervised hierarchical clustering of the human AML samples using the 140 gene (n ¼ 285 probeset) POU4F1 expression signature and found that the t(8;21) samples segregated into a distinct cluster ( Figure 5 ). As t(8;21) AML samples have a strong, reproducible expression signature, 9, 10 these samples might be predicted to cluster using many combinations of 285 probesets. We tested this hypothesis using a random sampling strategy and found that the t(8;21) samples cluster together rarely by chance when gene sets of identical size were used (Po0.05).
Limiting our comparison to the M2 AML patients (n ¼ 25), we found that the POU4F1 gene set again segregated the t(8;21) samples (not shown). When each signature gene was tested for differences in expression between samples with or without t(8;21), eight annotated genes were identified ( Table 1) . Four of these genes show marked (more than twofold), consistent upregulation in the t(8;21) samples, compared with other AML subtypes ( Figure 5) .
To determine which genes have significant differential expression independent of POU4F1 in t(8;21) AML samples, we used the Significance Analysis of Microarray algorithm after removing the POU4F1 gene set. A total of 115 annotated genes (183 probesets) remained significant in this comparison (Supplementary Table 4 ).
Discussion
Previous work has shown that expression of the AE fusion gene is not sufficient to induce AML. AE transcripts remain detectable in bone marrow cells from patients with t(8;21) AML in durable remission. 5, 28 Expression of an AE cDNA in transgenic mice [6] [7] [8] or by retroviral transduction/transplantation 29, 30 does not cause AML, unless additional mutations are induced. 6, 7, 29 Gene expression profiling experiments have implicated POU4F1 as a candidate cooperating factor in t(8;21) AML. 9, [23] [24] [25] [26] [27] In this study, we confirmed the observation that POU4F1 dysregulation is highly correlated with t(8;21) AML and explore the biological consequences of POU4F1 expression in hematopoietic cells.
Several lines of evidence indicate that POU4F1 dysregulation is not caused by AE. First, we ectopically expressed the AE cDNA in mouse and human cells by transfection, retroviral transduction or transgenesis and could not detect differences in POU4F1 expression under any of these conditions. These results are consistent with previous experiments in cell lines and transgenic zebrafish. [31] [32] [33] [34] Next, high POU4F1 expression is detectable in a minority of t(8;21)-negative AML cases, suggesting that AE is not required for its transcriptional activation. Finally, Pou4f1 is not expressed in normal hematopoietic or lymphoid cells 35 and is not required for hematopoiesis. 11, 13, 14 Taken together, this suggests that AE does not cause POU4F1 upregulation, nor does it cause POU4F1 levels to increase by expanding a cellular population that normally expresses POU4F1. Therefore, POU4F1 and AE are concordantly overexpressed in t(8;21) AML, but through independent mechanisms, suggesting that they provide non-redundant signals important for leukemogenesis.
These results support a model in which POU4F1 upregulation precedes acquisition of the t (8;21) . This raises many questions for future investigation, including the following: What genetic and/or epigenetic mechanism(s) activate POU4F1? Do POU4F1-dependent signals facilitate acquisition of the t (8;21) or provide a selective advantage for cells that undergo this translocation? Do POU4F1 and AE cooperate during induction of leukemia in vivo?
POU4F1 is a member of the highly conserved family of POU domain-containing transcription factors. Although we showed that Pou4f1 is dispensable for self-renewal of hematopoietic progenitors in vitro, transplantation experiments will be required to address the importance of this factor for pluripotency and selfrenewal of hematopoietic stem cells in vivo. The closely related POU family member, POU5F1 (encoding OCT4), is required to maintain pluripotency in embryonic stem cells 36 and elevated levels drive their differentiation along mesodermal and endodermal lineages. 37 POU5F1 has also been implicated in carcinogenesis. It is overexpressed in breast and germ cell tumors. 38, 39 Inducible expression in mice causes dysplasia in the skin and gastrointestinal tract. 40 Previous studies of POU4F1 have been restricted to neuronal cells, wherein it has been shown to promote cell survival and inhibit apoptosis, in part by antagonizing p53 and p73 to increase Bcl2 and Bax expression. 41, 42 In hematopoietic cells, we observed different effects of Pou4f1 on transcription and cell growth (in fact, Pou4f1 appears to restrain cell growth that was stimulated by AE). These apparently contradictory results may reflect differences in experimental design or cellular context. We adopted an unbiased approach to identify transcriptional targets of Pou4f1 in primary murine hematopoietic cells and then cross-validated this expression signature in primary human AML samples. The Pou4f1 expression signature is sufficient to cluster t(8;21) AML samples in an unsupervised analysis and the Pou4f1 gene set is enriched in t(8;21) AML, suggesting that the expression of these target genes discovered in mouse is relevant in human cells and preserved in fully transformed leukemias. Four of these genes (SOX, CAV1, ROBO1 and PPADC1B) are also regulated independently by AE. [32] [33] [34] The nerve growth factor receptor TrkA has also been shown to be a target of both Pou4f1 and AE. 43, 44 The other four genes in the POU4F1 signature (PELI2, FAM69B, H2AFV and PLXDC2) are POU4F1 specific (that is, they are overexpressed in t(8;21) AML samples, but not activated by AE). These results imply that the gene expression profile of t(8;21) AML is, in part, attributable to POU4F1 and not solely AE itself.
Several members of the Pou4f1 gene set have been previously implicated in cancer. SOX4 is a transcription factor important for the regulation of embryonic development and determination of cell fate. [45] [46] [47] Depending on context, SOX4 has both oncogenic [48] [49] [50] and tumor-suppressor properties. 51 SOX4 is activated by retroviral integration in mice, and cooperates with Evi1 in the induction of AML. 52 CAV1 is a lipid raft protein that binds to the G-protein-coupled receptor, GLP-1, and is involved in subcellular localization, trafficking and signaling. 53 In AML samples, CAV1 and MDR1 colocalize and their expression is highly correlated. 54 ROBO1 is a receptor for SLIT and interacts with Rho GTPase-activating proteins important for cell motility and angiogenesis. 55, 56 Downregulation of ROBO1 in breast cancer may initiate a metastatic phenotype. 57 PPADC1B encodes a transmembrane protein phosphatase that can induce anchorage-independent growth in 3T3 fibroblasts. 58 Although additional work is required to elucidate the mechanism by which POU4F1 contributes to t(8;21) AML, it is clear that this transcription factor is a critical driver of disordered gene expression in this disease. Further research on factors both upstream and downstream of POU4F1 should shed new light on the pathogenesis of t(8;21)-positive AML. 
